Advertisement
Advertisement
ALZN
Alzamend Neuro, Inc. Common Stock
1.93
USDSponsored
+0.11
+5.94%
Mar 25, 16:00 UTC -4
Closed
Pre-Market
2.12
+0.19
+9.84%
ALZN Earnings Reports
Positive Surprise Ratio
ALZN beat 9 of 17 last estimates.
53%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Alzamend Neuro, Inc. Common Stock earnings per share and revenue
On Mar 11, 2026, ALZN reported earnings of -0.57 USD per share (EPS) for Q3 26, beating the estimate of -1.96 USD, resulting in a 70.46% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.13% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were Alzamend Neuro, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Alzamend Neuro, Inc. Common Stock reported EPS of -$0.57, beating estimates by 70.46%, and revenue of $0.00, 0% as expectations.
How did the market react to Alzamend Neuro, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -4.13%, changed from $2.18 before the earnings release to $2.09 the day after.
When is Alzamend Neuro, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Alzamend Neuro, Inc. Common Stock's next earnings report?
Based on --
analysts, Alzamend Neuro, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement